Comparison · NCT00646399-6f071de1
Pagibaximab vs Placebo: The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pagibaximab vs Placebo: The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35. Trial comparisons, record NCT00646399-6f071de1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00646399-6f071de1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.107 | 0.0876 | 0.131 | wilson | |
| Risk in group 2 | 0.1 | 0.0813 | 0.123 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00694 | -0.0233 | 0.0372 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.8 | 1.43 | log | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.78 | 1.49 | log | |
| Number needed to treat, for one more participant with the outcome on Pagibaximab than on Placebo | 144 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pagibaximab | 85 | 792 | OG000 | |
| Group 2 | Placebo | 79 | 787 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.
- Description
- Safety and efficacy
- Time frame
- 35 days
- Population
- 1579 very low birth weight subjects were included in the ITT.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis
- NCT number
- NCT00646399
- Phases
- PHASE2, PHASE3
- Conditions
- Staphylococcal Sepsis
- Interventions
- Placebo, Pagibaximab 50 mg/mL
- Lead sponsor
- Biosynexus Incorporated
- Results first posted
- 2011-10-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00646399?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00646399-6f071de1